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Abstract
Background: Previous population-based studies have described first primary breast cancer tumor characteristics
and their association with contralateral breast cancer (CBC) risk. However, information on influential covariates such
as treatment, family history of breast cancer, and BRCA1/2 mutation carrier status was not available. In a large,
population-based, case-control study, we evaluated whether tumor characteristics of the first primary breast cancer
are associated with risk of developing second primary asynchronous CBC, overall and in subgroups of interest,
including among BRCA1/2 mutation non-carriers, women who are not treated with tamoxifen, and women without
a breast cancer family history.
Methods: The Women’s Environmental Cancer and Radiation Epidemiology Study is a population-based case-
control study of 1521 CBC cases and 2212 individually-matched controls with unilateral breast cancer. Detailed
information about breast cancer risk factors, treatment for and characteristics of first tumors, including estrogen
receptor (ER) and progesterone receptor (PR) status, was obtained by telephone interview and medical record
abstraction. Multivariable risk ratios (RRs) and 95% confidence intervals (CIs) were estimated in conditional logistic
regression models, adjusting for demographics, treatment, and personal medical and family history. A subset of
women was screened for BRCA1/2 mutations.
Results: Lobular histology of the first tumor was associated with a 30% increase in CBC risk (95% CI 1.0–1.6).
Compared to women with ER+/PR+ first tumors, those with ER-/PR- tumors had increased risk of CBC (RR = 1.4, 95%
CI 1.1–1.7). Notably, women with ER-/PR- first tumors were more likely to develop CBC with the ER-/PR- phenotype
(RR = 5.4, 95% CI 3.0–9.5), and risk remained elevated in multiple subgroups: BRCA1/2 mutation non-carriers, women
younger than 45 years of age, women without a breast cancer family history, and women who were not treated
with tamoxifen.
Conclusions: Having a hormone receptor negative first primary breast cancer is associated with increased risk of
CBC. Women with ER-/PR- primary tumors were more likely to develop ER-/PR- CBC, even after excluding BRCA1/2
mutation carriers. Hormone receptor status, which is routinely evaluated in breast tumors, may be used clinically to
determine treatment protocols and identify patients who may benefit from increased surveillance for CBC.
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Background
Among women with a first breast cancer, risk of a sec-
ond primary tumor in the contralateral breast is greater
than risk of a first primary breast cancer in the general
female population, [1–3] and contralateral breast cancer
(CBC) represents the most frequent new malignancy di-
agnosed among breast cancer survivors [4]. The 25-year
cumulative risk of CBC in the USA is approximately 7%,
[4] with some evidence that CBC incidence has recently
declined [5]. However, increases in breast cancer inci-
dence, coupled with advances in treatment and im-
proved survival, have led to a rise in the number of
breast cancer survivors at risk of CBC. Identified risk
factors for CBC include young age at first breast cancer
diagnosis, [2, 6] breast cancer family history, [1, 7–10]
mutations in BRCA1 and BRCA2 (BRCA1/2), [11, 12]
young age at menarche, [13] nulliparity, [13] and obesity
[14]. We and others have shown that both chemotherapy
[15, 16] and tamoxifen therapy [16, 17] are associated
with reduced CBC risk, although the benefit of tamoxi-
fen on CBC risk was limited to estrogen receptor-
positive (ER+) disease in the EBCTCG meta-analysis
[17]. We further demonstrated that current users of
tamoxifen with longer durations of use have the largest
CBC reduction, which adds further support for the re-
cent recommendations for primary breast cancer [18].
Additionally, some features of first breast tumors may
predict CBC risk. Lobular histology of the first primary
tumor has been associated with higher CBC incidence in
several [1, 8, 9, 19, 20] although not all studies [6, 21, 22].
Evidence of associations with other histologic parameters
remains equivocal [3, 23, 24]. Women with estrogen
receptor-negative (ER-) first primary tumors, particularly
those diagnosed at younger ages, may be at increased risk
of CBC, and appear more likely to have second tumors
that are ER- and high grade, [23, 25–29] potentially
reflecting a higher number of BRCA1 mutation carriers in
this group [30, 31]. ER and progesterone receptor (PR)
status, collectively referred to as hormone receptor (HR)
status, is routinely evaluated to inform treatment deci-
sions, and could potentially be used to identify women at
increased CBC risk. Tumors that lack expression of HR
(HR-), particularly those displaying the triple-negative
phenotype, are associated with poorer clinical outcomes
and presently there are fewer therapeutic options for
these tumors than for HR-positive (HR+) and HER2-
overexpressing tumors (HER2+) [32].
Several previous studies have examined characteristics
of first breast tumors in relation to CBC risk, using can-
cer registry data, primarily the US National Cancer Insti-
tute’s Surveillance, Epidemiology, and End Results
(SEER) Registry Program. Despite large sample sizes,
these studies generally lacked detailed information on
potentially important covariates including BRCA1/2
mutation carrier status, breast cancer family history, and
treatment for first breast cancer [25, 26, 28, 29]. Here,
we evaluate first primary breast cancer characteristics
and CBC risk in a population-based case-control study
of CBC cases and unilateral breast cancer (UBC)
controls.
Methods
Study population
The Women’s Environmental Cancer and Radiation
Epidemiology (WECARE) Study is a multicenter,
population-based case-control study in which UBC con-
trols were individually matched to (cases) with asyn-
chronous CBC. The study design of the first phase
(WECARE I Study) has been described in detail else-
where; [33] the second phase (WECARE II Study)
employed a nearly identical approach [16]. Briefly, par-
ticipants were identified through eight population-based
cancer registries: six in the USA, one in Canada, and
one in Denmark (Table 1). The study protocol was ap-
proved by the institutional review boards at each site
and the Ethics Committee System in Denmark.
Cases were participants who were: (1) diagnosed be-
tween 1985 and 2008 with a first invasive breast cancer
that had not spread beyond regional lymph nodes at
diagnosis and a second contralateral primary breast can-
cer at least 1 year after the first diagnosis; (2) younger
than 55 years at first diagnosis; (3) without previous or
intervening cancer diagnosis except non-melanoma skin
cancer or cervical carcinoma in situ; (4) alive at contact;
(5) willing to provide informed consent and a biospeci-
men; and (6) residents of the same cancer registry
reporting region for both diagnoses. Controls with an in-
tact contralateral breast were identified using the same
eligibility criteria, and individually matched to cases (1:2
in the WECARE I Study; 1:1 in the WECARE II Study)
on the following criteria: diagnosis age (5-year strata),
diagnosis year (4-year strata), cancer registry region,
and race/ethnicity. To improve statistical efficiency,
WECARE I Study cases and controls were additionally
counter-matched on cancer-registry-reported treatment
with radiation such that two members of the case-
control triad had received radiation therapy for their
index breast cancer.
We identified a total of 2354 CBC (cases) and 3599
UBC controls eligible for the study. Of those, 1521 pa-
tients and 2212 controls provided written informed con-
sent, completed the interview, and provided a
biospecimen.
Data collection
Study participants were interviewed by telephone using a
structured questionnaire to evaluate known or suspected
breast cancer risk factors, including demographics,
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medical history, reproductive history, breast cancer family
history, hormone use, smoking and alcohol intake. De-
tailed data on treatment, tumor characteristics including
HR status were abstracted from pathology and surgical
reports, radiation oncology clinic notes, and systemic
adjuvant treatment reports. Information on tumor charac-
teristics was also obtained from SEER registry records for
US participants and from the Danish Breast Cancer Co-
operative Group records for Danish participants. HER2
status was available only for WECARE II Study partici-
pants. ER, PR and HER2 status were each reported as
“positive” (+), “negative” (-) or “unknown”. Self-reported
treatment data were used for participants with missing in-
formation in their medical records (chemotherapy, 4%;
hormonal therapy, 5%).
Participants in the WECARE I Study were screened for
BRCA1/2 mutations using denaturing high-performance
liquid chromatography [34]. Carriers of BRCA1/2 muta-
tions were defined based on the presence of variants
known or predicted to truncate the protein including
frameshifts and premature termination codons, mutations
occurring within 2 bp of an intron/exon boundary,
and missense substitutions known to have deleterious
functional effects.
Statistical analysis
Data from the two study phases were combined for the
analyses presented here. Multivariable conditional logis-
tic regression models were fit to estimate adjusted risk
ratios (RRs) and corresponding 95% confidence intervals
(CIs). Models included the following known or sus-
pected CBC risk factors: age at first breast cancer diag-
nosis, breast cancer family history, age at menarche,
parity, menopausal status, lobular histology of first
breast cancer, and treatment for first breast cancer (hor-
monal, radiation therapy, chemotherapy). To account for
the counter-matched design of the WECARE I Study,
Table 1 Characteristics of cases and controls from the WECARE
Study population
Variable CBC cases
N = 1521
UBC controls
N = 2212
Age at first diagnosis (years),
median (range)
46 (24-54) 46 (23-54)
Age at reference date (years),
median (range)
53 (27-73) 52 (27-71)
Length of at-risk period (years)a,
median (range)
6.3 (1.0-19.8) 5.5 (1.0-19.8)
Study area, N (%)
Iowab
Californiac
Seattled
Denmarke
Canadaf
201 (13)
658 (43)
224 (15)
279 (18)
159 (10)
314 (14)
967 (44)
317 (14)
457 (21)
157 (7)
Year of first breast cancer diagnosis, N (%)
1985–1988
1989–1992
1993–1996
1997–2008
238 (16)
415 (27)
427 (28)
441 (29)
467 (21)
647 (29)
632 (29)
466 (21)
Age at menarche (years), N (%)
Never had menses
<13
≥13
Unknown
3 (0)
724 (48)
791 (52)
3 (0)
6 (0)
965 (44)
1239 (56)
2 (0)
Number of full-term pregnancies, N (%)
None
1
2
3
≥4
Unknown
322 (21)
271 (18)
559 (37)
256 (17)
108 (7)
5 (0)
412 (19)
341 (15)
842 (38)
387 (17)
225 (10)
5 (0)
Menopausal statusg, N (%)
Premenopausal
Postmenopausal
Unknown
1124 (74)
389 (26)
8 (1)
1676 (76)
522 (24)
14 (1)
First-degree family history of breast cancer, N (%)
No
Yes
Adopted/unknown
1004 (66)
497 (33)
20 (1)
1706 (77)
466 (21)
40 (2)
Stage of first diagnosis, N (%)
Local
Regional
Unknown
1061 (70)
448 (29)
12 (1)
1442 (65)
759 (34)
11 (1)
Chemotherapy, N (%)
No
Yes
699 (46)
822 (54)
923 (42)
1289 (58)
Radiation treatment, N (%)
No
Yes
Unknown
641 (42)
880 (58)
0 (0)
522 (24)
1689 (76)
1 (0)
BRCA1/2 deleterious mutations, N (%)
No 596 (39) 1322 (60)
Yes 109 (7) 76 (3)
Not testedh 816 (54) 814 (37)
Table 1 Characteristics of cases and controls from the WECARE
Study population (Continued)
Hormone treatment, N (%)
No
Yes
Unknown
964 (63)
557 (37)
0 (0)
1270 (57)
940 (42)
2 (0)
Abbreviations: WECARE Women’s Environmental Cancer and Radiation
Epidemiology Study, CBC contralateral breast cancer, UBC unilateral breast
cancer. aBeginning at least one year after first diagnosis and extending to the
date of CBC diagnosis of cases. bThe State Health Registry of Iowa. cFour study
centers: (1) Los Angeles County Cancer Surveillance Program, (2) The Cancer
Surveillance Program of Orange County/San Diego-Imperial Organization for
Cancer Control, (3) Greater Bay Area Cancer Registry (San Francisco Bay Area
Region and Santa Clara Region), and (4) Sacramento and Sierra Center Registry
(Sacramento Region). dCancer Surveillance System of the Fred Hutchinson Cancer
Research Center. eThe Danish Breast Cancer Cooperative Group Database
supplemented by the Danish Cancer Registry. fThe Ontario Cancer Registry.
gWomen were classified as premenopausal if they reported having menstrual
periods or being pregnant within 2 years of initial diagnosis. hOnly WECARE I
Study participants were screened for BRCA1/2 deleterious mutations
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models included a log-weight covariate. WECARE II
Study participants (who were not counter-matched)
were assigned an offset term of 1 [33]. During the study
period, clinical guidelines for tamoxifen evolved, which
is reflected in the reporting of this treatment in our
study. In 1988, tamoxifen was recommended for women
with lymph-node-negative breast cancer [35]. A decade
later, guidelines for women with ER+ breast cancer rec-
ommended adjuvant tamoxifen for 5 years [36, 37]. We
chose cut points of <5, 5–9, and ≥10 years for analysis
by time since the first breast cancer diagnosis and fur-
ther adjusted these estimates for tumor stage in view of
changing tamoxifen guidelines during the study period.
Previous work demonstrated that nearly all tumors clas-
sified as ER-/PR+ in medical records are re-classified by
either immunohistochemical analysis or gene expression
analysis; [38] therefore, RR estimates for first primary tu-
mors identified as ER-/PR+ are not reported in HR sta-
tus analyses. We evaluated associations of HR status of
the first breast tumor with risk of ER+/PR+, ER+/PR-
and ER-/PR- CBC. We examined CBC risk among 705
cases and 1398 controls who were tested for BRCA1/2
deleterious mutations, and repeated the analysis exclud-
ing BRCA1/2 mutation carriers. The association of HR
status of the first breast tumor with CBC risk and
subtype-specific CBC was additionally adjusted for
BRCA1 deleterious mutation status in a post-hoc ana-
lysis. Likelihood ratio tests were utilized to assess het-
erogeneity for potential effect modifiers, including
differences in all tumor characteristics and tamoxifen
between the WECARE I and WECARE II Studies (all
Pheterogeneity by study phase ≥0.17). Analyses were con-
ducted using SAS v9.4 (SAS Institute, Cary, NC, USA).
Results
Our analysis includes 1521 CBC cases and 2212 UBC
controls. There were 2107 participants in the WECARE
I Study and 1626 participants in the WECARE II Study.
Median age at first diagnosis was 46 years and median
time to CBC diagnosis among cases was 6.3 years
(Table 1). Overall, approximately 75% of participants
were premenopausal at first diagnosis.
Lobular histology of the first breast cancer was associ-
ated with elevated CBC risk (RR = 1.3, 95% CI 1.0–1.6)
(Table 2). This association was limited to non-users of
tamoxifen (users RR = 1.0, 95% CI 0.7–1.4; non-users
RR = 1.6, 95% CI 1.1–2.1, Pheterogeneity = 0.045). Other
features of the first tumor, including grade, stage, nodal
involvement, and tumor size, were not associated with
CBC risk.
Women whose first primary tumor was HR- had a
higher risk of CBC than women with HR+ disease
(Table 2). ER- first tumor status was associated with a
30% (95% CI 1.1–1.6) increase in CBC risk compared to
ER+ first tumors; similarly elevated risks were observed
when comparing PR- to PR+ first breast cancers (RR = 1.2,
95% CI 1.0–1.5). When ER and PR were evaluated jointly,
ER-/PR- first tumor status was associated with a higher
CBC risk than ER+/PR+ status of first tumors (RR = 1.4,
95% CI 1.1–1.7). Overall results for HR status were not
appreciably different in the subset of women who had not
received tamoxifen for their first diagnosis (1054 cases/
1425 controls; see Additional file 1). Among WECARE II
Study participants who were tested for HER2 status,
neither HER2 positivity (RR = 0.8, 95% CI 0.5–1.3)
nor the triple-negative phenotype (ER-/PR-/HER2-)
was statistically significantly associated with CBC risk
(RR = 1.3, 95% CI 0.8–2.2).
Although there was no statistically significant hetero-
geneity, for HR- tumors, the increased CBC risk was
greatest in the first 10 years following the first breast
cancer diagnosis, with no association seen among
women who were diagnosed with CBC more than
10 years after their first diagnosis (<5 years ER-/PR- vs.
ER+/PR+ RR = 1.5, 95% CI 1.1–2.1; ≥10 years ER-/PR-
vs. ER+/PR+ RR = 1.1, 95% CI 0.7–1.6) (Table 3). Similar
patterns according to time since first diagnosis were
observed among women who had not used tamoxifen
for their first breast cancer. The associations between
HR status of first tumor and CBC risk were not modified
by either first-degree breast cancer family history (any
family history ER-/PR- vs. ER+/PR+ RR = 1.5, 95% CI
1.1–2.3; no family history RR = 1.3, 95% CI 1.0–1.7,
Pheterogeneity = 0.43) or diagnosis age (<45 years ER-/PR-
vs. ER+/PR+ RR = 1.4, 95% CI 1.0–1.8; ≥45 years RR = 1.3,
95% CI 1.0–1.7, Pheterogeneity = 0.79).
Women diagnosed with an ER-/PR- first breast cancer
were less likely than women with an ER+/PR+ tumor to
develop ER+/PR+ CBC (RR = 0.7, 95% CI 0.5–1.0)
(Table 4). In contrast, the risk of developing an ER-/PR-
CBC was fivefold greater among women with ER-/PR-
first breast cancer than among those with ER+/PR+ first
cancer (RR = 5.4, 95% CI 3.0–9.5). There was no effect
modification by age, family history, or tamoxifen ther-
apy; elevated RRs of ER-/PR- CBC following ER-/PR-
first breast cancer were also observed for women
<45 years of age at first diagnosis (RR = 5.9, 95% CI
2.9–12.2), those without family history of breast cancer
(RR = 5.2, 95% CI 2.8–9.7) and those who were not
treated with tamoxifen (RR = 6.5, 95% CI 3.2–12.9).
Among the women screened for BRCA1/2 mutations,
185 (109 cases, 76 controls) were mutation carriers. Ex-
cluding these women attenuated the increased RRs for
CBC observed among all women when comparing HR+
to HR- first breast cancers, but the increased risk of
ER-/PR- CBC following a diagnosis of an ER-/PR- first
tumor, compared to an ER+/PR+ first tumor, persisted
(all tested women RR = 7.6, 95% CI 3.0–19.5; non-
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carriers RR = 7.7, 95% CI 2.6–23.3) (Table 5). The find-
ings were similar when BRCA1 deleterious mutation
status was included in the multivariable model (all tested
women RR = 7.6, 95% CI 3.0–19.5; all tested women
adjusting for BRCA1 deleterious mutation status RR =
8.9, 95% CI 3.1–25.9). Excluding only BRCA1 carriers
yielded an effect of similar magnitude for the risk of
ER-/PR- CBC following an ER-/PR- first primary (results
not shown).
Discussion
In the WECARE Study, an HR- first breast cancer was
associated with greater CBC risk than an HR+ first
breast cancer. In particular, having a first tumor that
lacked both ER and PR expression was associated with a
more than fivefold greater risk of developing a CBC with
the same HR-defined phenotype than first tumors that
expressed both markers. Similar patterns of association
between HR- first primary tumors and overall and
subtype-specific CBC risk were observed when women
treated with tamoxifen were excluded, suggesting that
these associations were not due to lower CBC risk fol-
lowing tamoxifen treatment for ER+ first tumors. A
lobular versus non-lobular histologic assessment at first
diagnosis conferred a 30% increased CBC risk. Other
features of first breast cancers were not associated with
CBC risk.
Our analysis benefits from the collection of detailed
data on treatment history and potential confounders,
including reproductive and family history. Many previ-
ous analyses have relied on data from cancer registries,
including SEER, which records only limited covariate
data and intended first course treatment. Similar to our
results, the preponderance of studies indicate that HR-
Table 2 Association between tumor characteristics of first
primary breast cancer and contralateral breast cancer risk
First primary breast cancer Cases, N (%) Controls, N (%) RRa (95% CI)
Histology
Non-lobular 1338 (88) 1986 (90) 1.0 (ref.)
Lobular 179 (12) 223 (10) 1.3 (1.0, 1.6)
Unknown 4 (0) 3 (0)
Grade
Well 248 (16) 338 (15) 1.0 (ref.)
Moderate 417 (27) 688 (31) 0.8 (0.7, 1.1)
Poor/undifferentiated 503 (33) 640 (29) 1.1 (0.8, 1.4)
Unknown 353 (23) 546 (25)
Stage
Localized 1061 (70) 1442 (65) 1.0 (ref.)
Regional 448 (29) 759 (34) 1.0 (0.9, 1.2)
Unknown 12 (1) 11 (1)
Lymph node status
Negative 1045 (69) 1426 (64) 1.0 (ref.)
Positive 438 (29) 751 (34) 1.0 (0.8, 1.2)
No nodes sampled 22 (2) 26 (1) 1.3 (0.7, 2.4)
Unknown 16 (1) 9 (0)
Tumor size
≤10 mm 335 (22) 510 (23) 1.0 (ref.)
>10 to ≤20 mm 595 (39) 913 (41) 1.1 (0.9, 1.3)
>20 mm 477 (31) 662 (30) 1.1 (0.9, 1.4)
Inflammatory 6 (0) 2 (0)
Unknown 108 (7) 125 (6)
ER status
Positive 797 (52) 1254 (57) 1.0 (ref.)
Negative 467 (31) 561 (25) 1.3 (1.1, 1.6)
Other/unknownb 257 (17) 397 (18)
PR status
Positive 687 (45) 1083 (49) 1.0 (ref.)
Negative 442 (29) 549 (25) 1.2 (1.0, 1.5)
Other/unknownb 392 (26) 580 (26)
Joint ER/PR status
ER+/PR+ 621 (41) 958 (43) 1.0 (ref.)
ER+/PR- 85 (6) 142 (6) 1.0 (0.7, 1.4)
ER-/PR- 352 (23) 387 (18) 1.4 (1.1, 1.7)
Other/unknownb,c 463 (30) 725 (33)
HER2 statusd
Negative 207 (25) 222 (27) 1.0 (ref.)
Positive 53 (7) 63 (8) 0.8 (0.5, 1.3)
Unknownb 553 (68) 528 (65)
Table 2 Association between tumor characteristics of first
primary breast cancer and contralateral breast cancer risk
(Continued)
Triple-negatived
No 514 (63) 579 (71) 1.0 (ref.)
Yes 59 (7) 40 (5) 1.3 (0.8, 2.2)
Other/unknownb 240 (30) 194 (24)
Abbreviations: RR risk ratio, CI confidence interval, N number, ER estrogen
receptor, PR progesterone receptor, HER2 human epidermal growth factor
receptor 2. aAdjusted for age at first breast cancer diagnosis, first-degree
family history of breast cancer, histologic assessment, menopausal status, age
at menarche, parity, radiation, chemotherapy and hormone therapy at first
breast cancer diagnosis. Model examining histology was not adjusted for
histologic assessment. b“Other/unknown” category consists of women for
whom no laboratory test was given, the test was given and the results were
unknown or the test was given and the results were borderline; estimates not
reported. The start date for ER/PR reporting in SEER was 1 January 1990 [47].
cIncludes 59 cases and 108 controls classified as ER-/PR+. dAmong participants
in the Women’s Environmental Cancer and Radiation Epidemiology II Study
(WECARE II) only; HER2 status not queried for WECARE I participants.
Surveillance, Epidemiology, and End Results (SEER) Registry only began
collecting HER2 status in 2010 [46]
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first breast tumors are associated with increased CBC
risk. In a population-based case-control study that ad-
justed for treatment information available in SEER,
Saltzman et al. reported that women with ER-/PR- first
breast cancer were 60% more likely to be diagnosed with
CBC than those with ER+/PR+ tumors, [28] a risk esti-
mate comparable to our findings. In two of the largest
and most recent US registry-based studies assessing
combined HR status of first tumors and CBC risk, CBC
risk was higher among [26] or limited to [25] women
with HR- first tumors than among those with HR+ dis-
ease, although neither study adjusted for treatment.
However, an analysis in the Stockholm Breast Cancer
Registry, which included data on endocrine therapy but
few other covariates, found no difference in CBC risk by
ER status of the first tumor (ER+ standardized incidence
ratio (SIR) = 2.30 vs. ER- SIR = 2.17) [29]. PR status was
not examined.
Consistent with our findings that women with ER-/
PR- first breast cancers are at particularly high risk of
ER-/PR- CBC, several other studies have found high
concordance between HR status of the first and second
primary breast cancers [22, 27, 29, 39]. Whether the
high concordance between HR status of the first and
second primary breast tumors reflects an underlying
genetic susceptibility or an individual’s exposure to
Table 3 Association between HR status of first breast cancer and CBC risk, by time since diagnosis
Time <5 years to CBC Time 5 to <10 years to CBC Time ≥10 years to CBC
N (cases/controls) RRa (95% CI) N (cases/controls) RRa (95% CI) N (cases/controls) RRa (95% CI) P-heterogeneity
All women, tumor status at first diagnosis
ER status
Positive 306/585 1.0 (ref.) 293/440 1.0 (ref.) 198/229 1.0 (ref.)
Negative 186/241 1.4 (1.1, 1.9) 186/209 1.3 (1.0, 1.8) 95/111 1.0 (0.7, 1.5) 0.37
Other/unknownb 94/160 95/155 68/82
PR status
Positive 262/477 1.0 (ref.) 249/395 1.0 (ref.) 176/211 1.0 (ref.)
Negative 183/238 1.3 (1.0, 1.8) 169/203 1.3 (1.0, 1.8) 90/108 0.9 (0.6, 1.4) 0.26
Other/unknownb 141/271 156/206 95/103
Joint ER/PR status
ER+/PR+ 239/423 1.0 (ref.) 219/351 1.0 (ref.) 163/184 1.0 (ref.)
ER+/PR- 38/68 1.0 (0.6, 1.6) 31/48 1.2 (0.7, 2.2) 16/26 0.6 (0.3, 1.3)
ER-/PR- 145/166 1.5 (1.1, 2.1) 136/145 1.5 (1.0, 2.0) 71/76 1.1 (0.7, 1.6) 0.45
Other/unknownb,c 164/329 188/260 111/136
Women who did not receive tamoxifen treatment for first diagnosis, tumor status at first diagnosis
ER status
Positive 169/290 1.0 (ref.) 141/196 1.0 (ref.) 97/108 1.0 (ref.)
Negative 169/212 1.4 (0.9, 2.1) 166/173 1.4 (0.9, 2.0) 87/92 1.1 (0.7, 1.9) 0.77
Other/unknownb 85/142 80/135 60/77
PR status
Positive 135/222 1.0 (ref.) 117/165 1.0 (ref.) 84/102 1.0 (ref.)
Negative 159/187 1.4 (0.9, 2.1) 145/160 1.3 (0.8, 2.0) 82/82 1.3 (0.7, 2.2) 0.97
Other/unknownb 129/235 125/179 78/93
Joint ER/PR status
ER+/PR+ 121/185 1.0 (ref.) 97/136 1.0 (ref.) 75/83 1.0 (ref.)
ER+/PR- 24/31 1.3 (0.6, 2.7) 16/26 0.7 (0.3, 2.0) 12/13 1.6 (0.4, 6.2)
ER-/PR- 135/152 1.4 (0.9, 2.3) 127/125 1.5 (0.9, 2.4) 67/64 1.3 (0.7, 2.4) 0.84
Other/unknownb,c 143/276 147/217 90/117
Abbreviations: HR hormone receptor, CBC contralateral breast cancer, RR risk ratio, CI confidence interval, N number, ER estrogen receptor, PR
progesterone receptor
aAdjusted for age at first breast cancer diagnosis, first-degree family history of breast cancer, histologic assessment, stage, menopausal status, age at menarche,
parity, radiation, chemotherapy and hormone therapy at first breast cancer diagnosis. b“Other/unknown” category consists of women for whom no laboratory test
was given, the test was given and the results were unknown or the test was given and the results were borderline; estimates not reported. cIncludes tumors
classified as ER-/PR+
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hormonal or other risk factors is presently unknown and
difficult to determine. It has been established that risk
factors for first primary breast cancer vary across breast
cancer subtypes defined by HR status or molecular
subtypes based on distinct gene expression signatures
[40–42]. Thus, phenotypic concordance between two
primary tumors may be due, at least in part, to exposure
to subtype-specific risk factors [43]. Certain genetic mu-
tations may additionally predispose individuals to devel-
oping breast cancer subtypes. In particular, ER- tumors
are prevalent among BRCA1 mutation carriers, [30, 31]
which we hypothesize could explain some of the high
risk of ER-/PR- CBCs following an ER-/PR- first breast
cancer observed in this and in other studies. In our
study, the high risk of ER-/PR- CBC following a first
tumor with the same phenotype persisted after we ex-
cluded BRCA1/2 mutation carriers. BRCA1 mutation
carriers also tend to develop breast cancer at a relatively
young age and other studies have reported that risk of
HR- CBC among those with an HR- first tumor was
higher among younger women [26, 27, 39]; we did not
observe differences by age in our younger population.
Furthermore, risks did not appear to differ by breast
cancer family history, a possible indicator of underlying
genetic susceptibility. It is likely that a combination of
both exogenous and endogenous factors, including gen-
etic or molecular factors not measured here, play a role
in the development of two cancers with a shared HR-
defined phenotype.
Histologic identification of lobular cancer in situ and in-
vasive first breast cancer has frequently been implicated as
a risk factor for CBC. Here, we observed a statistically sig-
nificant 30% increased CBC risk associated with histologic
identification of a lobular first tumor, even after adjusting
for treatment and other risk factors. This result is consist-
ent with that observed in previous studies [2, 20, 43],
although one large population-based study found no
elevation in CBC risk comparing lobular with ductal first
tumors [21]. Some older studies were conducted prior to
the widespread use of endocrine therapy, while a substan-
tial proportion of receptor-positive women in our study
received tamoxifen treatment. As virtually all classic lobu-
lar tumors are ER+, [44] treatment with tamoxifen may
have lowered subsequent CBC risk among women with
histologic identification of lobular cancer; accordingly, we
observed that histologic identification of lobular cancer
was associated with significantly increased CBC risk
among women who had not been treated with tamoxifen.
Our study population included women under age
55 years at diagnosis of their first primary tumor. There-
fore, the results of this study are most relevant for
young women with breast cancer. A limitation of our
study is the lack of BRCA1/2 mutation data for
WECARE II Study participants, reducing the statistical
power to detect associations among non-carriers. Small
numbers of ER+/PR- tumors also limited our ability to
examine associations with this subtype. Additionally,
HR status was evaluated by the pathology departments
of treating hospitals, and was not assessed centrally
using a standardized protocol. However, previous work
has shown good agreement between HR status reported
in cancer registries and HR status determined in a single
Table 4 Association between hormone receptor status of first breast cancer and subtype-specific contralateral breast cancer
ER+/PR+ CBC ER+/PR- CBC ER-/PR- CBC
Tumor status at first diagnosis N (cases/controls) RRa (95% CI) N (cases/controls) RRa (95% CI) N (cases/controls) RRa (95% CI)
ER status
Positive 365/421 1.0 (ref.) 123/147 1.0 (ref.) 89/241 1.0 (ref.)
Negative 95/182 0.6 (0.4, 0.9) 55/67 0.9 (0.5, 1.6) 187/112 3.9 (2.4, 6.5)
Other/unknownb 74/80 16/42 31/55
PR status
Positive 321/386 1.0 (ref.) 109/130 1.0 (ref.) 81/214 1.0 (ref.)
Negative 106/184 0.8 (0.6, 1.1) 52/63 0.9 (0.5, 1.5) 183/115 3.8 (2.3, 6.3)
Other/unknownb 107/113 33/63 43/79
Joint ER/PR status
ER+/PR+ 307/343 1.0 (ref.) 97/112 1.0 (ref.) 64/193 1.0 (ref.)
ER+/PR- 30/50 0.7 (0.4, 1.2) 14/15 1.2 (0.5, 2.7) 20/28 2.6 (1.1, 5.7)
ER-/PR- 74/130 0.7 (0.5, 1.0) 38/48 0.8 (0.4, 1.5) 162/83 5.4 (3.0, 9.5)
Other/unknownb,c 123/160 45/81 61/104
Abbreviations: CBC contralateral breast cancer, RR risk ratio, CI confidence interval, N number, ER estrogen receptor, PR progesterone receptor
aAdjusted for age at first breast cancer diagnosis, first-degree family history of breast cancer, histologic assessment, menopausal status, age at menarche, parity,
radiation, chemotherapy and hormone therapy at first breast cancer diagnosis. b“Other/unknown” category consists of women for whom no laboratory test was
given, the test was given and the results are unknown or the test was given and the results were borderline; estimates not reported. cIncludes tumors classified
as ER-/PR+
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academic reference laboratory, particularly for ER+/PR+
and ER-/PR- subtypes [45]. Additionally, misclassifica-
tion of HR status is unlikely to be related to case-
control status; as such, any resulting bias will likely be
toward the null. We were not able to examine potential
effect modification by use of aromatase inhibitors,
which lower estrogen levels and have been used in the
treatment of ER+ breast tumors in postmenopausal
women. Given the relatively young age of participants and
because most first breast cancers in our study occurred
prior to the widespread use of these drugs, few women in
our study population received this therapy. Last, many of
the women in our study were diagnosed prior to the iden-
tification of HER2 and its incorporation into clinical prac-
tice [46]. Therefore, we lacked data on HER2 expression
for a large proportion of our participants, affecting our
statistical power and limiting our ability to classify tumors
into categories that more closely approximate currently
recognized molecular subtypes.
Conclusions
In summary, we observed that HR status and lobular
histology of a first breast cancer are predictive of CBC
risk. In particular, after adjusting for known CBC risk
factors including treatment, women with an ER-/PR-
first breast cancer were at a high risk of developing a
second breast cancer that was also ER-/PR-. As HR sta-
tus is a key factor in treatment choice, and ultimately
prognosis, these results are informative for risk stratifi-
cation. Notably, BRCA1 mutation carriers are known to
be at high risk of HR- tumors and CBC, but these asso-
ciations were also seen in BRCA1/2 non-carriers. These
results suggest that HR status may be useful for
informing counseling and screening strategies for
CBC risk among women with a first breast cancer.
Future work should focus on more refined classifica-
tion of both first and subsequent primary breast can-
cers in order to clarify whether these tumors arise
from similar etiologic pathways and to identify pa-
tients at high risk of CBC.
Additional file
Additional file 1: Table S1. Association between first breast cancer HR
status and CBC, among women not receiving tamoxifen for first diagnosis.
In the WECARE Study population of women who had not received
tamoxifen for their first breast cancer diagnosis, having an ER-negative first
breast cancer or a PR-negative first breast cancer statistically significantly
increased the risk of CBC. (DOCX 19 kb)
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